Regenxbio, Duchenne muscular dystrophy and gene therapy
Regenxbio Share Surge 20% on Duchenne Muscular Dystrophy Treatment Trial Data, Expansion
Regenxbio shares surged 20% after disclosing new, positive efficacy and safety data of its Duchenne muscular dystrophy treatment. Shares were recently trading around $11.55. The stock is down 46% on the year.
Regenxbio is pushing its Duchenne muscular dystrophy gene therapy into pivotal development, with a BLA planned for ...
REGENXBIO Inc. (Nasdaq: RGNX) today announced that AFFINITY DUCHENNE®, the multi-center, open-label trial of RGX-202, a ...
Bank of America Securities analyst Alec Stranahan maintained a Buy rating on RegenXBio (RGNX – Research Report) yesterday and set a price ...
Trump fingers Robert F. Kennedy Jr. to lead the HHS, lupus and ATTR-CM dominate headlines this week, bluebird bio has a cash gap to leap and RegenxBio eyes Sarepta in Duchenne muscular dystrophy.
Regenxbio’s investigational gene therapy improved muscle function for patients with Duchenne muscular dystrophy (DMD) in a phase 1/2 study. | Regenxbio’s investigational gene therapy improved muscle ...
a potential best-in-class gene therapy for Duchenne muscular dystrophy, has advanced to pivotal stage and dosed its first patient. The company also announced new, positive efficacy and safety ...
Elevidys, a gene therapy from Sarepta Therapeutics (SRPT.O), opens new tab approved in the United States last year for ...
It’s easy for those who play or watch the best movies based on video games to want to be immersed in that fictional world.
DICKSON CITY, Pa. — The Eagle Hose Company in Dickson City on Saturday, November 16 hosted a benefit for the Hetzel family as ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback